TY - JOUR
T1 - Obesity, height, and serum androgen metabolism among postmenopausal women in the women's health initiative observational study
AU - Oh, Hannah
AU - Wild, Robert A.
AU - Manson, Jo Ann E.
AU - Bea, Jennifer W.
AU - Shadyab, Aladdin H.
AU - Pfeiffer, Ruth M.
AU - Saquib, Nazmus
AU - Underland, Lisa
AU - Anderson, Garnet L.
AU - Xu, Xia
AU - Trabert, Britton
N1 - Funding Information:
The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005 (Program Office: Jacques Rossouw, Shari Ludlam, Joan McGowan, Leslie Ford, and Nancy Geller). The authors thank the WHI Clinical Coordinating Center (Fred Hutchinson Cancer Research Center) and the WHI investigators (G.L. Anderson, Ross Prentice, Andrea LaCroix, Charles Kooperberg, J.E. Manson, Barbara V. Howard, Marcia L. Stefanick, Rebecca Jackson, Cynthia A. Thomson, Jean Wactawski-Wende, Marian Limacher, Jennifer Robinson, Lewis Kuller, Sally Shumaker, Robert Brunner) for their dedication, and the study participants for making the program possible. A full list of WHI investigators can be found at https://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Long%20List. pdf. This study was also supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics of the NCI. H. Oh was supported by the National Research Foundation of Korea (NRF) grant (2019R1G1A1004227, 2019S1A3A2099973). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Received May 13, 2021; revised July 15, 2021; accepted August 17, 2021; published first August 26, 2021.
Funding Information:
H. Oh reports grants from National Research Foundation of Korea during the conduct of the study. R.A. Wild reports other support from Ablacare and grants from National Institute of Child Health and Human Resources outside the submitted work. J.E. Manson reports grants from NIH during the conduct of the study. J.W. Bea is member of Global Health and Body Composition Institute Board of Directors. G.L. Anderson reports grants from NHLBI during the conduct of the study. No disclosures were reported by the other authors.
Funding Information:
The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005 (Program Office: Jacques Rossouw, Shari Ludlam, Joan McGowan, Leslie Ford, and Nancy Geller). The authors thank the WHI Clinical Coordinating Center (Fred Hutchinson Cancer Research Center) and
Funding Information:
This study was also supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics of the NCI. H. Oh was supported by the
Publisher Copyright:
© 2021 American Association for Cancer Research
PY - 2021/11
Y1 - 2021/11
N2 - Background: Anthropometric measures, including obesity, are important risk factors for breast and endometrial cancers in postmenopausal women. It is unknown whether these risk factors are associated with androgen metabolism, another risk factor for these cancers. Methods: Using baseline data from 1,765 postmenopausal women in the Women's Health Initiative Observational Study, we conducted a cross-sectional analysis examining associations between anthropometric measures [current body mass index (BMI), waist-to-hip ratio (WHR), height, and recalled BMI at age 18) and serum androgen metabolites. Twelve androgens/androgen metabolites were quantified using LC-MS/MS. Geometric means of androgen/androgen metabolite concentrations were estimated using linear regression, adjusting for potential confounders and stratified by hormone therapy (HT) use. Results: Regardless of HT use, higher current BMI (≥30 vs. <25 kg/m2) was associated with higher serum concentrations of dehydroepiandrosterone sulfate (DHEAS), 5a-reduced glucuronide metabolites [androsterone-glucuronide (ADT-G), 5a-androstane-3a,17b diol-3-glucuronide (3a-diol-3G), 3a-diol-17-glucuronide (3a-diol-17G)], and DHEAS:DHEA ratio (all P trend ≤ 0.02). BMI was also positively associated with unconjugated estrone:androstenedione and unconjugated estradiol:testosterone ratios among never/former HT users (all P trend < 0.001) but not among current users (P-int < 0.001). WHR was positively associated with adrenal androgens and 5a-reduced glucuronide metabolites in obese women only (BMI ≥ 30 kg/m2; all P-trend ≤ 0.01). BMI at age 18 was inversely associated with adrenal androgens (DHEA, DHEAS, androstenedione, testosterone) and 5a-reduced glucuronide metabolites in never/former HT users (all P trend < 0.06). Height was not associated with androgen metabolites. Conclusions: Current BMI is associated with androgen metabolism among postmenopausal women. Impact: This study contributes to our understanding of the link between obesity and cancer risk in postmenopausal women.
AB - Background: Anthropometric measures, including obesity, are important risk factors for breast and endometrial cancers in postmenopausal women. It is unknown whether these risk factors are associated with androgen metabolism, another risk factor for these cancers. Methods: Using baseline data from 1,765 postmenopausal women in the Women's Health Initiative Observational Study, we conducted a cross-sectional analysis examining associations between anthropometric measures [current body mass index (BMI), waist-to-hip ratio (WHR), height, and recalled BMI at age 18) and serum androgen metabolites. Twelve androgens/androgen metabolites were quantified using LC-MS/MS. Geometric means of androgen/androgen metabolite concentrations were estimated using linear regression, adjusting for potential confounders and stratified by hormone therapy (HT) use. Results: Regardless of HT use, higher current BMI (≥30 vs. <25 kg/m2) was associated with higher serum concentrations of dehydroepiandrosterone sulfate (DHEAS), 5a-reduced glucuronide metabolites [androsterone-glucuronide (ADT-G), 5a-androstane-3a,17b diol-3-glucuronide (3a-diol-3G), 3a-diol-17-glucuronide (3a-diol-17G)], and DHEAS:DHEA ratio (all P trend ≤ 0.02). BMI was also positively associated with unconjugated estrone:androstenedione and unconjugated estradiol:testosterone ratios among never/former HT users (all P trend < 0.001) but not among current users (P-int < 0.001). WHR was positively associated with adrenal androgens and 5a-reduced glucuronide metabolites in obese women only (BMI ≥ 30 kg/m2; all P-trend ≤ 0.01). BMI at age 18 was inversely associated with adrenal androgens (DHEA, DHEAS, androstenedione, testosterone) and 5a-reduced glucuronide metabolites in never/former HT users (all P trend < 0.06). Height was not associated with androgen metabolites. Conclusions: Current BMI is associated with androgen metabolism among postmenopausal women. Impact: This study contributes to our understanding of the link between obesity and cancer risk in postmenopausal women.
UR - http://www.scopus.com/inward/record.url?scp=85118966759&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-21-0604
DO - 10.1158/1055-9965.EPI-21-0604
M3 - Article
C2 - 34446472
AN - SCOPUS:85118966759
SN - 1055-9965
VL - 30
SP - 2018
EP - 2029
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 11
ER -
